A randomised phase II trial comparing the efficacy of single fraction or multi-fraction SABR (Stereotactic ablative body radiotherapy) with AteZolizumab in patients with advanced Triple nEgative breast Cancer
Primary Sponsor
Victorian Comprehensive Cancer Centre (VCCC)
Collaborating Groups
Trans Tasman Radiation Oncology Group (TROG)
Accrual Target
32
Final Accrual
32
Closing Date of Accrual
22 November 2022
Trial Chairperson
Dr Steven David, Peter MacCallum Cancer Centre, VIC
Related Post
13 November, 2024
Trek4TROG team rise to Blue Mountains challenge
November 2024: Congratulations to the Trek4TROG team for successfully
24 October, 2024
Promising new results from RAIDER trial published
24 October 2024: Newly published findings from the TROG
